Table 2. Distribution of quinolone resistance phenotypes among S. Typhi haplotypes.
Haplotype | NalR | NalS | Total | |||
CipS | CipI | CipR | All | |||
H58 subtypes | ||||||
- A | 14 | 3 | 0 | 17 | 5 | 22 |
- B | 23 | 13 | 0 | 36 | 112 | 148 |
- E2 | 1 | 0 | 0 | 1 | 0 | 1 |
- G | 43 | 20 | 0 | 63 | 2 | 65 |
- G0 | 1 | 0 | 0 | 1 | 0 | 1 |
- H64 | 12 | 5 | 0 | 17 | 0 | 17 |
- H65 | 1 | 0 | 0 | 1 | 0 | 1 |
- I1 | 0 | 0 | 2* | 2 | 0 | 2 |
- I3 | 1 | 0 | 0 | 1 | 0 | 1 |
- I4 | 1 | 0 | 0 | 1 | 0 | 1 |
- K1 | 1 | 0 | 0 | 1 | 0 | 1 |
All H58 | 98 | 41 | 2* | 141 | 119 | 260 |
H14 | 14 | 5 | 0 | 19 | 6 | 25 |
H16 | 1 | 0 | 0 | 1 | 4 | 5 |
H42 | 24 | 6 | 0 | 30 | 35 | 65 |
H50 | 4 | 0 | 0 | 4 | 2 | 6 |
H85 | 5 | 0 | 0 | 5 | 0 | 5 |
Other | 1 | 0 | 0 | 1 | 5 | 6 |
Total | 147 | 52 | 2* | 201 | 171 | 372 |
Haplotypes are defined in Figure 1. NalS: Nalidixic acid susceptible (MIC<8 µg/mL); NalR: Nalidixic acid resistant (MIC>256 µg/mL); CipS: ciprofloxacin susceptible (MIC<0.125 µg/mL); CipI: ciprofloxacin reduced susceptible (MIC≥0.125 µg/mL); CipR: ciprofloxacin resistant (MIC>1 µg/mL);
*Cip MIC>16 µg/mL.